Call to action – a novel strategy to improve clinical trial recruitment.

The article focuses on challenges and innovations in patient recruitment for molecularly targeted oncology clinical trials, using the Breast Cancer Trials (BCT) Olaparib + ImmunOtherapy (OLIO) trial as a case study. It highlights that strict molecular eligibility criteria, such as homologous recombi...

Descripción completa

Detalles Bibliográficos
Publicado en:Internal Medicine Journal Vol. 56; no. 7; pp. 1268 - 1270
Autores principales: Zardawi, Sarah, Zdenkowski, Nicholas, Hay, Tracey, Badger, Heath
Formato: letter Journal Article
Publicado: Wiley-Blackwell Jul2026
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=195683467&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 195683467
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        14440903
        HYC
      jtl: Internal Medicine Journal
      issn: 14440903
      maglogo: Y
    pubinfo:
      dt: Jul2026
      vid: 56
      iid: 7
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        195683467
        195175234
        195683467
        195683467
        10.1111/imj.70492
        195683467
      ppf: 1268
      ppct: 2
      formats:
      tig:
        atl: Call to action – a novel strategy to improve clinical trial recruitment.
      aug:
        au:
          Zardawi, Sarah
          Zdenkowski, Nicholas
          Hay, Tracey
          Badger, Heath
        affil: Trials Department, Breast Cancer Trials, Newcastle New South Wales,, Australia
      sug:
        subj:
          Clinical Trials
          Research Subject Recruitment
          Strategic Planning
          Oncologic Care
          Eligibility Determination
          Cancer Screening
          Tumor Markers, Biological
          Breast Neoplasms
          Neoadjuvant Therapy
          Chemotherapy, Cancer
          Telehealth
          Rural Areas
          Oncologists
          Remote Patient Monitoring
      ab: The article focuses on challenges and innovations in patient recruitment for molecularly targeted oncology clinical trials, using the Breast Cancer Trials (BCT) Olaparib + ImmunOtherapy (OLIO) trial as a case study. It highlights that strict molecular eligibility criteria, such as homologous recombination deficiency (HRD) status, limit patient enrollment, prompting the removal of such criteria in OLIO due to low recruitment. To address these challenges, BCT developed a remote telehealth pre-screening process to facilitate molecular testing and patient identification across non-trial sites, aiming to broaden access and improve trial participation. Despite limited uptake among clinicians during the OLIO pilot, the approach shows potential for wider application, though barriers remain in data management and system compliance. The article calls for increased clinician engagement with telehealth pre-screening and further innovation to enhance recruitment efficiency and trial generalizability in oncology research.
      pubtype: Academic Journal
      doctype:
        letter
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N